Treprostinil for pulmonary hypertension

Treprostinil for pulmonary hypertension

Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medicione II, Vienna General Hospital, Medical University of Vienna, Austria; 2Department of Cardiology, Erasme University Hospital, Brussels, BelgiumAbstract: Treprostinil is a stable, long-acting prostacy...

Full description

Bibliographic Details
Main Authors:	Nika Skoro-Sajer, Irene Lang, Robert Naeije
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-06-01
Series:	Vascular Health and Risk Management
Online Access:	https://www.dovepress.com/treprostinil-for-pulmonary-hypertension-peer-reviewed-article-VHRM

Similar Items

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
by: Carlo Arevalo, et al.
Published: (2022-01-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
by: Pavel Jansa, et al.
Published: (2023-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01)

Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function
by: Aleksandra Judina, et al.
Published: (2023-12-01)

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension
by: Yoo-Jin Kim, et al.
Published: (2024-01-01)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
by: Adrián Lescano, et al.
Published: (2022-10-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
by: Asuka Furukawa, et al.
Published: (2017-10-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
by: Marcin Kurzyna, et al.
Published: (2017-12-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-07-01)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
by: Ifeoma Oriaku, et al.
Published: (2020-03-01)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-01-01)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
by: Felix Rafael De Bie, et al.
Published: (2022-07-01)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
by: James C. Coons, et al.
Published: (2018-03-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
by: John W. Swisher, PhD, MD, et al.
Published: (2017-01-01)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy
by: Maria Laggner, et al.
Published: (2022-01-01)

EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension
by: Maria Laggner, et al.
Published: (2022-04-01)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
by: Jeremy P. Feldman, et al.
Published: (2021-03-01)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
by: Marcin Waligóra, et al.
Published: (2023-02-01)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
by: R. James White, et al.
Published: (2020-12-01)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
by: Diane L. Zwicke, et al.
Published: (2021-03-01)

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension
by: James C. Coons, et al.
Published: (2021-04-01)

Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation
by: Alex J. Chang, MD, et al.
Published: (2024-03-01)

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study
by: Enhuan Wei, et al.
Published: (2023-11-01)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
by: Manuel J. Richter, et al.
Published: (2020-03-01)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
by: James C. Coons, et al.
Published: (2017-11-01)

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network
by: Emma O. Jackson, et al.
Published: (2021-03-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
by: Jan C. Kamp, et al.
Published: (2021-05-01)

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
by: Justin J. Kochanski, et al.
Published: (2024-01-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
by: Shelsey W. Johnson, et al.
Published: (2022-07-01)

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
by: Travis Maestas, et al.
Published: (2018-08-01)

The right ventricle in pulmonary arterial hypertension
by: Robert Naeije, et al.
Published: (2014-12-01)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
by: Lei Fang, et al.
Published: (2023-07-01)